Labopharm Reports Results for Third Quarter F...(----------------------------------------...),Health

444 563 1,646 1,211

-------------------------------------------------------------------------

-------------------------------------------------------------------------

NET LOSS FOR THE PERIOD (9,031) (4,361) (26,539) (16,700)

-------------------------------------------------------------------------

-------------------------------------------------------------------------

NET LOSS PER SHARE -

BASIC AND DILUTED (0.16) (0.08) (0.47) (0.33)

-------------------------------------------------------------------------

-------------------------------------------------------------------------

Weighted average number

of common shares

outstanding 56,817,963 56,747,093 56,795,545 50,938,493

-------------------------------------------------------------------------

-------------------------------------------------------------------------

INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

For the: Three months ended Nine months ended

Sept 30, Sept 30, Sept 30, Sept 30,

2007 2006 2007 2006

(Thousands of Canadian

dollars) $ $ $ $

-------------------------------------------------------------------------

OPERATING ACTIVITIES

Net loss for the period (9,031) (4,361) (26,539) (16,700)

Items not affecting cash:

Depreciation of property,

plant and equipment 448 375 1,304 1,105

Amortization of intangible

assets 62 55 178 171

Amortizatio
'/>"/>